TNFSF11 and neoplasm: For [64Cu]Cu-NOTA-denosumab, significantly higher tumor uptake could be observed between RANKL-ME-180 and ME-180 xenografts, respectively (7.43 ± 0.27 vs. 4.20 ± 0.45% ID/g, p < 0.0001) (Figure 6D).